What is the role of beta-blockers in heart failure with reduced ejection fraction (HFrEF)?

• A. They primarily increase contractility to improve ejection fraction.
• B. They increase aldosterone synthesis.
• C. They have no effect on mortality.
• D. They improve survival by reducing mortality, remodeling, and arrhythmia risk after initiation and stabilization.

Answer: (C)

Beta-blockers in heart failure with reduced ejection fraction work by dampening chronic sympathetic activation. In HFrEF, long‑term high catecholamine levels drive worsening remodeling, worsen contractile function, and raise arrhythmia risk. By blocking beta-1 receptors, these drugs slow the heart rate and lessen myocardial stress, which over time leads to reverse remodeling, improved ventricular function, and a lower risk of sudden death from arrhythmias. This survival benefit is seen after careful initiation and uptitration once the patient is stabilized, because starting too aggressively can acutely reduce contractility. They do not boost aldosterone production; if anything, they help blunt the RAAS axis by reducing renin release. So the best description is that beta-blockers improve survival by reducing mortality, remodeling, and arrhythmia risk after initiation and stabilization.